Analysis of Enterprises' Technological Innovation Paths Under the Impact of Industrial Policies ——Evidence from Enterprises Involved in Centralized Procurement
Feng Yuqi1 ,Liu Li1,2, Yuan Xilin1,3
1. School of Economics and Management, Southeast University, Nanjing 211189, China; 2. National Key Laboratory of Low-Carbon and Intelligent Coal-Fired Power Generation and Ultra-Clean Emission (Southeast University), Nanjing 211189, China; 3. Institute for Scientific and Technical Information, Southeast University, Nanjing 211189, China
Abstract：The impact of industrial policies on innovation varies among different enterprises,and analysing the innovation paths of enterprises under the established policies can provide practical insights for enterprises to optimise their innovation paths and for the government to improve industrial policies.Focusing on the pharmaceutical industry and taking the national centralized drug procurement policy as an example,the paper selects seven batches of selected listed companies within five years of the policy's implementation as research samples.Based on the TOE theory,it proposes six factors affecting the innovation of the selected companies:research and development (R&D)intensity,digital technology application level,internal R&D personnel,external cooperation,market competition,and government subsidies.On this basis,NCA and fsQCA are used to explore the interaction between these six antecedent factors and innovation of the selected enterprises in centralized procurement.A certain degree of external cooperation and government subsidy are necessary conditions for high innovation performance of the selected enterprises in centralized procurement,and the latter is more important than the former;there are three types of configurations of these selected listed companies to achieve high innovation performance,namely “innate endowment”, “synergy”and “self-motivation”.Meanwhile,there are also five configurations that lead to non-high innovation performance;the selected enterprises can only achieve innovation by deploying and linking the three dimensions of technology,organisation and environment on demand.
[1]侯方宇,杨瑞龙.产业政策有效性研究评述[J].经济学动态,2019(10):101-116. [2]黎文靖,郑曼妮.实质性创新还是策略性创新:宏观产业政策对微观企业创新的影响[J].经济研究,2016,51(4):60-73. [3]林志帆,黄新飞,李灏桢.何种产业政策更有助于企业创新:选择性还是功能性:基于中国制造业上市公司专利数据的经验研究[J].财政研究,2022(1):110-129. [4]单伟,孙一中,施萧萧,等.组态视角下专精特新“小巨人”企业高质量发展驱动机制研究[J].中国软科学,2025 (1):108-116. [5]杨玉龙,顾佳苗.带量采购政策能否倒逼医药企业创新:以恒瑞医药为例[J].中国管理会计,2023(2):94-105. [6]周卫.带量采购政策对上市药企创新的影响研究[D].成都:电子科技大学,2023. [7]蔡显军,卞宇轩,陈怡锋.药品集采与企业创新投入[J].科学决策,2023(12):102-118. [8]刘晓婷,吕豪.从被动支付到战略购买:药品集采对医药企业的影响研究[J/OL].南开管理评论,1-23[2024-08-24].http://kns.cnki.net/kcms/detail/12.1288.F.20240611.1026.002.html. [9]余巧萍.我国公立医院药品带量采购实施效果评价研究:以安徽省安庆市公立医院为例[J].价格理论与实践,2021(8):65-68. [10]黄羽舒,陶立波.药品集中带量采购对我国医药产业集中度的影响:基于产业经济学视角的分析[J].中国医疗保险,2020(2):64-67. [11]宋世俊,王崇鑫,张华静.TOE框架下公共数字文化服务供给效率的提升路径研究:基于模糊集定性比较分析[J].情报资料工作,2022,43(6):79-86. [12]余艳,王雪莹,毛基业.数字化投资与认知互补增效:高层梯队理论视角[J].管理科学学报,2024,27(4):41-64. [13]王宛秋,王雪晴,刘晓燕,等.基于TOE框架的企业跨界技术并购绩效的提升策略研究:一项模糊集的定性比较分析[J].南开管理评论,2022,25(2):136-148. [14]王伦,林润辉,张红娟,等.流水不腐还是墨守成规:企业研发人员稳定性对创新质量的影响[J].中国科技论坛,2023(9):91-101. [15]张征,谢佳,李冉.企业突破性创新的组态路径研究[J].科研管理,2024,45(7):21-28. [16]李钧,段帅航,王振源.“技术-组织-环境”因素联动对企业数字创新的影响:基于新一代信息技术企业的QCA分析[J].科技管理研究,2024,44(11):131-140. [17]荆浩,张耀耀,马佳,等.数字化转型背景下“专精特新”企业双元能力提升组态路径研究[J].科技管理研究,2023,43(22):164-174. [18]蒋殿春,卜文超.反垄断法与中国科技企业技术创新:基于不同市场地位企业的微观分析[J].数量经济技术经济研究,2023,40(7):27-47. [19]KAFUKU J M.Factors for effective implementation of lean manufacturing practice in selected industries in Tanzania [J].Procedia Manufacturing,2019,33(6):351-358. [20]杜运周,贾良定.组态视角与定性比较分析(QCA):管理学研究的一条新道路[J].管理世界,2017(6):155-167. [21]RIHOUX D B,RAGIN C C.Configurational comparative methods:Qualitative comparative analysis(QCA)and related techniques[M].Thousand Oaks:Sage,2009. [22]SCHNEIDER C Q,WAGEMANN C.Set-theoretic methods for the social sciences:A guide to qualitative comparative analysis[M].Cambridge:Cambridge University Press,2012. [23]黄嫚丽,张明,皮圣雷,等.中国企业逆向跨国并购整合组态与并购整合绩效关系研究[J].管理学报,2019,16(5):656-664. [24]GRECKHAMER T.CEO compensation in relation to worker compensation across countries:The configurational impact of country-level institutions[J].Strategic Management Journal,2016,37(4),793-815. [25]DING H E.What kinds of countries have better innovation performance?A country-level fsQCA and NCA study[J].Journal of Innovation & Knowledge,2022,7(4):12. [26]DUL J.Necessary condition analysis(NCA):Logic and methodology of“necessary but not sufficient”causality[J].Organizational Research Methods,2016,19(1):10-52. [27]DUL J.Identifying single necessary conditions with NCA and fsQCA[J].Journal of Business Research,2016,69(4):1516-1523. [28]任海云,谢秀翎,王博文.医药制造企业是营销制胜还是研发制胜[J].科研管理,2023,44(8):78-88. [29]唐孝文,姚欣岑,于岚婷.数字化背景下“小巨人”企业创新路径研究[J].科研管理,2023,44(12):10-20. [30]李文茜,刘益.技术创新、企业社会责任与企业竞争力:基于上市公司数据的实证分析[J].科学学与科学技术管理,2017,38(1):154-165. [31]吴非,胡慧芷,林慧妍,等.企业数字化转型与资本市场表现:来自股票流动性的经验证据[J].管理世界,2021,37(7):130-144,10. [32]赵宸宇.数字化发展与服务化转型:来自制造业上市公司的经验证据[J].南开管理评论,2021,24(2):149-163. [33]刘慧芬.商业信用、市场地位与技术创新:来自制造业上市公司的证据[J].经济问题,2017(4):12-17. [34]林峰.勒纳指数存在“悖论”吗:基于中国民航运输业市场势力的测度[J].财经科学,2013(8):58-66. [35]杨国超,芮萌.高新技术企业税收减免政策的激励效应与迎合效应[J].经济研究,2020,55(9):174-191. [36]吴伟伟,张天一.非研发补贴与研发补贴对新创企业创新产出的非对称影响研究[J].管理世界,2021,37(3):137-160,10. [37]杜运周,刘秋辰,陈凯薇,等.营商环境生态、全要素生产率与城市高质量发展的多元模式:基于复杂系统观的组态分析[J].管理世界,2022,38(9):127-145. [38]RAGIN C.Set relation in social research:Evaluating their consistency and coverage [J].Political Analysis,2006(3):291-310 [39]DUL J,VAN DER LAAN E,KUIK R.A statistical significance test for necessary condition analysis[J].Organizational Research Methods,2020,23(2):385-395. [40]DUL J,VIS B,GOERTZ G.Necessary condition analysis(NCA)does exactly what it should do when applied properly:A reply to a comment on NCA[J].Sociological Methods & Research,2021,50(2):926-936. [41]RAGINC C.Measurement versus calibration:A set theoretic approach[M].Oxford:The Oxford Handbook of Political Methodology,2008. [42]DUL J,HAUFF S,BOUNCKEN R B.Necessary condition analysis(NCA):Review of research topics and guidelines for good practice[J].Review of Managerial Science,2023,17(2):683-714. [43]林艳,卢俊尧.什么样的数字创新生态系统能提高区域创新绩效:基于NCA与QCA的研究[J].科技进步与对策,2022,39(24):19-28. [44]FISS P C.A set-theoretic approach to organizational configurations[J].Academy of Management Review,2007,32(4):1180-1198. [45]杜运周,刘秋辰,程建青.什么样的营商环境生态产生城市高创业活跃度:基于制度组态的分析[J].管理世界,2020,36(9):141-155. [46]中国青年网.自主研发+合作开发 碰撞创新“火花”[EB/OL].(2022-11-16)[2024-07-04].https://df.youth.cn/dfzl/202211/t20221116_14135357.htm. [47]台州人社.博士后工作站风采,国家级博士后科研工作站之浙江仙琚制药股份有限公司[EB/OL].(2021-04-29)[2024-07-04].https://mp.weixin.qq.com/s/Y2Hy1xmS7JDUPhe5olxrVA. [48]巨潮网.上海现代制药股份有限公司2020年年度报告摘要[EB/OL].(2024-07-04)[2024-07-04].https://static.cninfo.com.cn/finalpage/2021-03-26/1209453242.PDF. [49]华创证券.信立泰研究报告:走出集采影响,创新引领新增长[EB/OL].(2021-03-26)[2024-07-13].https://xueqiu.com/9508834377/235814912. [50]清华大学经济与管理学院.恒瑞医药:跨越创新的陷阱与断层[EB/OL].(2021-12-02)[2024-07-13].https://www.sem.tsinghua.edu.cn/info/1173/32545.htm. [51]四川经济网.从科伦药业新旧动能转换看成都工业互联网赋能成都智造[EB/OL].(20224-05-12)[2024-07-13].https://www.163.com/dy/article/H76A2H9K0550A2NP.html. [52]山东鲁抗医药.优秀创新案例精选:智慧运营工业互联网平台建设及应用——山东鲁抗医药股份有限公司[EB/OL].(2023-04-28)[2024-07-13].https://mp.weixin.qq.com/s/WaaCJybdIbqd8tLomxa3PA. [53]天风证券.数字化转型+并购,综合性医药龙头再启航[EB/OL].(2022-02-09)[2024-07-13].https://pdf.dfcfw.com/pdf/H3_AP202202091545909755_1.pdf. [54]张明,杜运周.组织与管理研究中QCA方法的应用:定位、策略和方向[J].管理学报,2019,16(9):1312-1323.
2026, 
